ID
17654
Descripción
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Tarceva Consent and Eligibility
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palabras clave
Versiones (2)
- 2/8/16 2/8/16 -
- 27/9/16 27/9/16 -
Subido en
27 de septiembre de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Descripción
Open-label Tarceva Eligibility
Descripción
Open-label Tarceva Eligibility
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1516637
Descripción
Eligibility Criteria: OSI-774-302 Protocol Version 2, 21 November 2007, Appendix 12.9
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1302261
Descripción
Eligibility Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1516637
Descripción
Eligibility Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1516637
Descripción
Eligibility Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1516637
Descripción
Eligibility Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1516637
Descripción
Exemption
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Descripción
Investigator Signature
Descripción
I have reviewed all data for this patient's eligibility and confirm that consent has been obtained in accordance with the GCP Directive (2005/28/EC) or EU Directive (2001/20/EC) and other applicable GCP requirements.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C2346576
Descripción
Investigator Signature Date
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Similar models
Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C1135136 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])